• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024

    10/23/24 7:30:55 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EBS alert in real time by email

    GAITHERSBURG, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, November 6, 2024, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2024, recent business developments, and financial outlook for full year 2024.

    Webcast & Conference Call Information

    Participants can access the conference call live via webcast. To join via telephone, please use the following dial-in details:

    • U.S. / New York: +1-646-968-2525
    • U.S. & Canada (Toll Free): +1-888-596-4144
    • Conference ID: 5259189

    A replay of the call can be accessed from the Investors page of Emergent's website.

    About Emergent BioSolutions

    At Emergent, our mission is to protect and enhance life. For 25 years, we've been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.

    Investor Contact:

    Richard S. Lindahl

    Executive Vice President, CFO

    [email protected]

    Media Contact:

    Assal Hellmer

    Vice President, Communications

    [email protected]



    Primary Logo

    Get the next $EBS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • When is the Emergent BioSolutions conference call scheduled?

      The conference call will take place on November 6, 2024, at 5:00 pm eastern time.

    • How can participants join the conference call?

      Participants can access the conference call via a live webcast or by dialing in using the provided telephone numbers.

    • What topics will be discussed during the conference call?

      The conference call will cover the financial results for the third quarter of 2024 and the financial outlook for the full year of 2024.

    • Where can participants find a replay of the conference call?

      A replay of the conference call can be accessed from the Investors page on Emergent's website.

    • What is the mission and business focus of Emergent BioSolutions?

      Emergent BioSolutions develops vaccines and therapeutics for public health threats and provides contract development and manufacturing services.

    Recent Analyst Ratings for
    $EBS

    DatePrice TargetRatingAnalyst
    12/30/2024$15.00Buy
    H.C. Wainwright
    8/22/2024$16.00Buy
    Rodman & Renshaw
    3/7/2024$5.00Hold → Buy
    The Benchmark Company
    11/20/2023Underweight
    JP Morgan
    8/29/2023Buy → Hold
    The Benchmark Company
    4/10/2023$22.00Hold → Buy
    The Benchmark Company
    3/17/2023$23.00 → $9.00Neutral → Underweight
    JP Morgan
    11/10/2022Buy → Hold
    The Benchmark Company
    More analyst ratings